Who's Afraid Of Big Pharma? Perhaps The Rare Disease Community
This article was originally published in The Pink Sheet Daily
Executive Summary
Concerns are growing that large companies entering the rare disease space will "ruin the market" and decrease the number of orphan product approvals.
You may also be interested in...
Pharma Industry Pushes A Broadened Meaning For “Orphan”
BOSTON – Along with the surge in interest in drugs to treat rare or orphan diseases, there has been an increasingly strategic view of what qualifies as an orphan market, with companies looking to subdivide conditions to capitalize on the perceived advantages afforded by rare diseases, according to participants at the recent BioPharm America conference.
Pharma Industry Pushes A Broadened Meaning For “Orphan”
BOSTON – Along with the surge in interest in drugs to treat rare or orphan diseases, there has been an increasingly strategic view of what qualifies as an orphan market, with companies looking to subdivide conditions to capitalize on the perceived advantages afforded by rare diseases, according to participants at the recent BioPharm America conference.
Pricing Rare Disease Drugs Requires Care As Payers Increase Scrutiny
Value questions are expected to be asked by payers and others as larger pharma companies enter the orphan drug space and more treatments debut targeting rare diseases.